

Glenn Chertow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6031900/publications.pdf>

Version: 2024-02-01

583
papers

67,201
citations

1238

110
h-index

834

245
g-index

594
all docs

594
docs citations

594
times ranked

42243
citing authors

#	ARTICLE	IF	CITATIONS
1	Removing Race from eGFR calculations: Implications for Urologic Care. <i>Urology</i> , 2022, 162, 42-48.	1.0	8
2	The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 136-144.	2.9	13
3	Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. , 2022, 32, e1-e14.		9
4	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	5.2	53
5	Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 12.e23-12.e30.	1.6	3
6	Twenty-four-hour Urine Testing and Urinary Stone Disease Recurrence in Veterans. <i>Urology</i> , 2022, 159, 33-40.	1.0	4
7	COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 33-37.	6.1	46
8	SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients. <i>Kidney360</i> , 2022, 3, 10.34067/KID.0005732021.	2.1	9
9	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1647-1656.	0.7	48
10	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 24-34.	11.4	40
11	Dysgeusia and Dysosmia in Chronic Kidney Disease: NHANES 2011-2014. , 2022, 32, 537-541.		2
12	Quã©telet (body mass) index and effects of dapagliflozin in chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 827-837.	4.4	8
13	Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Open Science</i> , 2022, 35, 29-36.	0.4	2
14	Cardiovascular outcomes associated with prescription of sodiumâ€¦glucose coâ€¦transporterâ€¦2 inhibitors versus dipeptidyl peptidaseâ€¦4 inhibitors in patients with diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 928-937.	4.4	2
15	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. <i>Kidney International Reports</i> , 2022, 7, 699-707.	0.8	6
16	Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2022, 37, 3380-3387.	2.6	15
17	Emerging Role of Clinical Genetics in CKD. <i>Kidney Medicine</i> , 2022, 4, 100435.	2.0	12
18	SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. <i>Annals of Internal Medicine</i> , 2022, 175, 371-378.	3.9	55

#	ARTICLE	IF	CITATIONS
19	Breaking the Barriers to Innovation in Kidney Care. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 591-593.	4.5	3
20	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.	0.8	36
21	Changing the Trajectory of Heart Failure and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, , CJN.00470122.	4.5	2
22	Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017. <i>JAMA Network Open</i> , 2022, 5, e221847.	5.9	11
23	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. <i>Journal of the American Heart Association</i> , 2022, 11, e022003.	3.7	6
24	SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1036-1038.	4.5	16
25	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 753-766.	2.9	31
26	Trends in Coronary Artery Disease Screening before Kidney Transplantation. <i>Kidney360</i> , 2022, 3, 516-523.	2.1	1
27	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	6.3	28
28	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
29	MO536: Cardiovascular Events in Patients With Anemia Associated With Non-Dialysis-Dependent Chronic Kidney Disease: Regional Analysis of Patients not Previously Treated With Erythropoiesis-Stimulating Agents in The PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
30	MO532: Cardiovascular Events in Patients With Non-Dialysis-Dependent Chronic Kidney Disease and Anemia: Regional Analysis of Patients Previously Treated With Erythropoiesis-Stimulating Agents in the PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
31	Reply. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1093-1094.	2.9	0
32	Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. <i>JAMA Cardiology</i> , 2022, 7, 825.	6.1	2
33	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.7	20
34	Innovation in hemodialysis: Using the Biodesign process to identify unmet needs. <i>Journal of Vascular Access</i> , 2021, 22, 509-514.	0.9	5
35	Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. <i>Hemodialysis International</i> , 2021, 25, 78-85.	0.9	3
36	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85

#	ARTICLE	IF	CITATIONS
37	Toward telemedicine-compatible physical functioning assessments in kidney transplant candidates. <i>Clinical Transplantation</i> , 2021, 35, e14173.	1.6	9
38	Laboratory-wide association study of survival with prostate cancer. <i>Cancer</i> , 2021, 127, 1102-1113.	4.1	6
39	Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?. <i>American Journal of Kidney Diseases</i> , 2021, 77, 478-480.	1.9	3
40	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 22-31.	11.4	287
41	Race and Place in ESKD. <i>Kidney International Reports</i> , 2021, 6, 252-253.	0.8	0
42	Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F133-F144.	2.7	7
43	Prolonged Hospitalization Following Acute Respiratory Failure. <i>Chest</i> , 2021, 159, 1867-1874.	0.8	5
44	Self-care training using the Tablo hemodialysis system. <i>Hemodialysis International</i> , 2021, 25, 12-19.	0.9	0
45	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	2.7	9
46	Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD. <i>Clinical and Translational Science</i> , 2021, 14, 299-309.	3.1	18
47	Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 366-374.	2.9	8
48	The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis. <i>CardioRenal Medicine</i> , 2021, 11, 174-183.	1.9	0
49	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. <i>American Journal of Nephrology</i> , 2021, 52, 180-189.	3.1	31
50	Performance versus Risk Factor-Based Approaches to Coronary Artery Disease Screening in Waitlisted Kidney Transplant Candidates. <i>CardioRenal Medicine</i> , 2021, 11, 140-150.	1.9	1
51	And Then There Were Three: Effects of Pretransplant Dialysis on Multiorgan Transplantation. <i>Transplantation Direct</i> , 2021, 7, e657.	1.6	3
52	Cost Structures of US Organ Procurement Organizations. <i>Transplantation</i> , 2021, 105, 2612-2619.	1.0	3
53	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. <i>BMC Nephrology</i> , 2021, 22, 69.	1.8	6
54	A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1465-1473.	6.1	45

#	ARTICLE	IF	CITATIONS
55	Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension. American Journal of Physiology - Renal Physiology, 2021, 320, F325-F335.	2.7	7
56	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. Kidney International Reports, 2021, 6, 1513-1524.	0.8	5
57	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European Heart Journal, 2021, 42, 1216-1227.	2.2	75
58	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. New England Journal of Medicine, 2021, 384, 1601-1612.	27.0	106
59	Targeting Sedentary Behavior in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 717-726.	4.5	12
60	Vadadustat in Patients with Anemia and Non-dialysis-Dependent CKD. New England Journal of Medicine, 2021, 384, 1589-1600.	27.0	137
61	SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. Journal of the American Society of Nephrology: JASN, 2021, 32, 1575-1581.	6.1	46
62	Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 736-745.	4.5	11
63	Laboratory correlates of SARS-CoV-2 seropositivity in a nationwide sample of patients on dialysis in the U.S.. PLoS ONE, 2021, 16, e0249466.	2.5	1
64	SNF472: mechanism of action and results from clinical trials. Current Opinion in Nephrology and Hypertension, 2021, 30, 424-429.	2.0	7
65	Estimated impact of novel coronavirus-19 and transplant center inactivity on end-stage renal disease-related patient mortality in the United States. Clinical Transplantation, 2021, 35, e14292.	1.6	3
66	The organ procurement costs of expanding deceased donor organ acceptance criteria: Evidence from a cost function model. American Journal of Transplantation, 2021, 21, 3694-3703.	4.7	4
67	Body Composition Changes Following Dialysis Initiation and Cardiovascular and Mortality Outcomes in CRIC (Chronic Renal Insufficiency Cohort): A Bioimpedance Analysis Substudy. Kidney Medicine, 2021, 3, 327-334.e1.	2.0	6
68	National Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race. Journal of the American Society of Nephrology: JASN, 2021, 32, 1454-1463.	6.1	28
69	MO518INSIDE CKD: MODELLING THE ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE IN THE AMERICAS AND THE ASIA-PACIFIC REGION USING PATIENT-LEVEL MICROSIMULATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
70	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care, 2021, 44, 1894-1897.	8.6	47
71	Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis. Journal of the American Society of Nephrology: JASN, 2021, 32, 2435-2438.	6.1	91
72	Reducing the Shortage of Transplant Kidneys: A Lost Opportunity for the US Health Resources and Services Administration (HRSA). American Journal of Kidney Diseases, 2021, 77, 963-966.	1.9	2

#	ARTICLE	IF	CITATIONS
73	Karnofsky Performance Score“Failure to Thrive as a Frailty Proxy?. Transplantation Direct, 2021, 7, e708.	1.6	6
74	Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 2303-2314.	6.1	27
75	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. Journal of Cardiac Failure, 2021, 27, 1447-1455.	1.7	14
76	Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis. Value in Health, 2021, 24, 1592-1602.	0.3	8
77	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. Kidney International Reports, 2021, 6, 1775-1787.	0.8	100
78	Patient-Reported Experiences with Dialysis Care and Provider Visit Frequency. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1052-1060.	4.5	0
79	Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2116572.	5.9	12
80	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 2021, 100, 215-224.	5.2	182
81	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 2352-2361.	6.1	88
82	Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis. Annals of Internal Medicine, 2021, 174, 1073-1080.	3.9	21
83	Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. Mayo Clinic Proceedings, 2021, 96, 2114-2122.	3.0	15
84	Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360, 2021, 2, 1600-1610.	2.1	12
85	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC: Heart Failure, 2021, 9, 807-820.	4.1	49
86	Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology, 2021, 155, 70-76.	1.0	6
87	Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis: A Cluster Randomized Trial. Kidney360, 2021, 2, 1752-1760.	2.1	4
88	AUTHOR REPLY. Urology, 2021, 155, 76.	1.0	0
89	Effect of a Home-Based Exercise Program on Indices of Physical Function and Quality of Life in Elderly Maintenance Hemodialysis Patients. Kidney and Blood Pressure Research, 2021, 46, 196-206.	2.0	13
90	Association of 152 Biomarker Reference Intervals with All-Cause Mortality in Participants of a General United States Survey from 1999 to 2010. Clinical Chemistry, 2021, 67, 500-507.	3.2	3

#	ARTICLE	IF	CITATIONS
91	The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
92	The Predialysis Serum Sodium Level Modifies the Effect of Hemodialysis Frequency on Left-Ventricular Mass: The Frequent Hemodialysis Network Trials. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 768-776.	2.0	2
93	Population-based identification and temporal trend of children with primary nephrotic syndrome: The Kaiser Permanente nephrotic syndrome study. <i>PLoS ONE</i> , 2021, 16, e0257674.	2.5	3
94	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 743-754.	11.4	87
95	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 755-766.	11.4	86
96	Obesity and Incident Kidney Disease: Busting the Myth of Metabolically Healthy Obesity. <i>American Journal of Kidney Diseases</i> , 2021, , .	1.9	0
97	Outcomes after left ventricular assist device implantation in patients with acute kidney injury. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 477-486.e3.	0.8	11
98	One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1769-1778.	0.7	25
99	Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2—lessons from evolution, the animal kingdom and rare progeroid syndromes. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2036-2045.	0.7	48
100	Toward Greater Scrutiny of Dialysate Flow: Reply to the Letter to the Editor of Dr. Molano-Triviño and Colleagues. <i>Blood Purification</i> , 2020, 49, 123-124.	1.8	0
101	Safety and efficacy of the Tablo hemodialysis system for in-center and home hemodialysis. <i>Hemodialysis International</i> , 2020, 24, 22-28.	0.9	10
102	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 75-84.	2.9	20
103	Preparing for Hemodialysis. , 2020, , 1157-1173.		1
104	Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis. <i>Circulation</i> , 2020, 141, 728-739.	1.6	104
105	Intradialytic Symptoms and Recovery Time in Patients on Thrice-Weekly In-Center Hemodialysis: A Cross-sectional Online Survey. <i>Kidney Medicine</i> , 2020, 2, 125-130.	2.0	13
106	Central venous pressure and the risk of diuretic-associated acute kidney injury in patients after cardiac surgery. <i>American Heart Journal</i> , 2020, 221, 67-73.	2.7	15
107	Effect of Intensive vs Standard Blood Pressure Treatment Upon Erectile Function in Hypertensive Men: Findings From the Systolic Blood Pressure Intervention Trial. <i>Journal of Sexual Medicine</i> , 2020, 17, 238-248.	0.6	7
108	A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. <i>Journal of Vascular Access</i> , 2020, 21, 467-474.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver& kidney Transplant as a Case Example. <i>Transplantation</i> , 2020, 104, 387-394.	1.0	13
110	Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. <i>Lancet</i> , The, 2020, 396, 1335-1344.	13.7	257
111	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	27.0	2,523
112	Correlates and Consequences of High Serum Irisin Concentration in Patients on Hemodialysis: A Longitudinal Analysis. , 2020, 31, 389-396.		2
113	Does really central venous pressure affect the risk of diuretic-associated acute kidney injury after cardiac surgery?. <i>American Heart Journal</i> , 2020, 226, 252.	2.7	0
114	Alport Syndrome Classification and Management. <i>Kidney Medicine</i> , 2020, 2, 639-649.	2.0	45
115	Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones. <i>JAMA Surgery</i> , 2020, 155, 861.	4.3	26
116	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.7	107
117	Patient&reported outcomes from the investigational device exemption study of the Tablo hemodialysis system. <i>Hemodialysis International</i> , 2020, 24, 480-486.	0.9	2
118	Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis &” Subgroup Analyses of the CALIPSO Trial. <i>Kidney International Reports</i> , 2020, 5, 2178-2182.	0.8	11
119	Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Hypertension</i> , 2020, 76, 1725-1733.	2.7	4
120	The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1878-1884.	8.6	31
121	Safety-Net Care for Maintenance Dialysis in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 424-433.	6.1	5
122	Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 616-623.	0.7	5
123	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	27.0	310
124	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1619-1628.	27.0	56
125	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
126	Early Delays in Insurance Coverage and Long-term Use of Home-based Peritoneal Dialysis. <i>Medical Care</i> , 2020, 58, 632-642.	2.4	9

#	ARTICLE	IF	CITATIONS
127	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 274-282.	0.7	168
128	Screening Rates for Primary Aldosteronism in Resistant Hypertension. <i>Hypertension</i> , 2020, 75, 650-659.	2.7	92
129	AKI—A Relevant Safety End Point?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 508-512.	1.9	13
130	Targeting Vascular Calcification in Chronic Kidney Disease. <i>JACC Basic To Translational Science</i> , 2020, 5, 398-412.	4.1	95
131	Dedicated kidney disease—focused outcome trials with sodium—glucose cotransporter—2 inhibitors: Lessons from CRENDENCE and expectations from DAPA—HF, DAPA—CKD, and EMPA—KIDNEY. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 46-54.	4.4	36
132	Osteoporosis, Fractures, and Bone Mineral Density Screening in Veterans With Kidney Stone Disease. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 872-878.	2.8	11
133	Physical Performance Testing in Kidney Transplant Candidates at the Top of the Waitlist. <i>American Journal of Kidney Diseases</i> , 2020, 76, 815-825.	1.9	17
134	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. <i>American Journal of Kidney Diseases</i> , 2020, 76, 842-850.	1.9	4
135	The —Advancing American Kidney Health—Executive Order: Challenges and Opportunities for the Large Dialysis Organizations. <i>American Journal of Kidney Diseases</i> , 2020, 76, 731-734.	1.9	13
136	Urinary Stone Disease in Pregnancy: A Claims Based Analysis of 1.4 Million Patients. <i>Journal of Urology</i> , 2020, 203, 957-961.	0.4	12
137	Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. <i>Kidney360</i> , 2020, 1, 368-375.	2.1	7
138	Patient and Provider Characteristics Associated With Sodium—Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease. <i>Clinical Diabetes</i> , 2020, 38, 240-247.	2.2	9
139	The Urine Albumin-to-Creatinine Ratio and Kidney Function after Nephrectomy. <i>Journal of Urology</i> , 2020, 204, 231-238.	0.4	9
140	The ongoing search for a robust clinical prediction model of ICU AKI. <i>Clinical Nephrology</i> , 2020, 93, 160-162.	0.7	1
141	Market Consolidation and Mortality in Patients Initiating Hemodialysis. <i>Value in Health</i> , 2019, 22, 69-76.	0.3	7
142	Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 802-810.	0.7	38
143	Prevalence of twenty-four hour urine testing in Veterans with urinary stone disease. <i>PLoS ONE</i> , 2019, 14, e0220768.	2.5	8
144	Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107402.	2.3	25

#	ARTICLE	IF	CITATIONS
145	Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. <i>Kidney International Reports</i> , 2019, 4, 987-994.	0.8	12
146	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1495-1504.	6.1	53
147	Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1523-1533.	6.1	41
148	Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. <i>American Journal of Hypertension</i> , 2019, 32, 1170-1177.	2.0	2
149	Association of Hospitalization and Mortality Among Patients Initiating Dialysis With Hemodialysis Facility Ownership and Acquisitions. <i>JAMA Network Open</i> , 2019, 2, e193987.	5.9	13
150	Percutaneous Kidney Biopsy and the Utilization of Blood Transfusion and Renal Angiography Among Hospitalized Adults. <i>Kidney International Reports</i> , 2019, 4, 1435-1445.	0.8	10
151	Current Status of Angiotensin Receptor Blocker Recalls. <i>Hypertension</i> , 2019, 74, 1275-1278.	2.7	12
152	Effects of Selonsertib in Patients with Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1980-1990.	6.1	72
153	Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107423.	2.3	2
154	Differential Molecular Modeling Predictions of Mid and Conventional Dialysate Flows. <i>Blood Purification</i> , 2019, 47, 369-376.	1.8	3
155	Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis. <i>American Journal of Nephrology</i> , 2019, 49, 125-132.	3.1	9
156	Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 261-267.	4.5	48
157	Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 346-353.	6.1	29
158	Chronic Kidney Disease and the Adiposity Paradox: Valid or Confounded?. , 2019, 29, 521-528.		12
159	Prospective Biopsy-Based Study of CKD of Unknown Etiology in Sri Lanka. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 224-232.	4.5	27
160	Challenges in Assessing the Burden of Hospitalized Heart Failure in End-Stage Kidney Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 534-536.	1.7	0
161	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019, 96, 1030-1036.	5.2	26
162	Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 641-652.	6.1	83

#	ARTICLE	IF	CITATIONS
163	Hypertension Hot Potato “Anatomy of the Angiotensin-Receptor Blocker Recalls. <i>New England Journal of Medicine</i> , 2019, 380, 1589-1591.	27.0	37
164	Treatment of metabolic acidosis with an intestinal binder. <i>Lancet, The</i> , 2019, 393, 1387-1388.	13.7	2
165	An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. <i>PLoS ONE</i> , 2019, 14, e0213774.	2.5	12
166	Paying for Hemodialysis in Kerala, India: A Description of Household Financial Hardship in the Context of Medical Subsidy. <i>Kidney International Reports</i> , 2019, 4, 390-398.	0.8	28
167	Relative sarcopenia and mortality and the modifying effects of chronic kidney disease and adiposity. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 338-346.	7.3	28
168	Removing Disincentives to Kidney Donation: A Quantitative Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1349-1357.	6.1	21
169	Exploring Care Attributes of Nephrologists Ranking Favorably on Measures of Value. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2464-2472.	6.1	4
170	Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease—Related Medications in Veterans. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1773-1780.	4.5	12
171	Acute Kidney Injury in Children Hospitalized With Diarrheal Illness in the United States. <i>Hospital Pediatrics</i> , 2019, 9, 933-941.	1.3	6
172	Estimated Effects of Early Diuretic Use in Critical Illness. , 2019, 1, e0021.		4
173	Frailty Among Patients Receiving Hemodialysis: Evolution of Components and Associations With Mortality. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 380-386.	3.6	42
174	Prior Hospitalization Burden and the Relatedness of 30-Day Readmissions in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 323-335.	6.1	12
175	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	1.9	18
176	Payer Type, Race/Ethnicity, and the Timing of Surgical Management of Urinary Stone Disease. <i>Journal of Endourology</i> , 2019, 33, 152-158.	2.1	22
177	Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1115-1124.	0.7	36
178	Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 90-99.	0.7	62
179	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 339-346.	0.7	28
180	Modification of eGFR-Based CKD Definitions: Perfect, or Enemy of the Good?. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1807-1809.	6.1	8

#	ARTICLE	IF	CITATIONS
181	Asymmetric dimethylarginine, erythropoietin resistance, and anemia in CKD. <i>Annals of Translational Medicine</i> , 2019, 7, S86-S86.	1.7	1
182	Updates in Management and Timing of Dialysis in Acute Kidney Injury. <i>Journal of Hospital Medicine</i> , 2019, 14, 232.	1.4	2
183	Testing two (of several) intravenous iron dosing strategies in hemodialysis. <i>Annals of Translational Medicine</i> , 2019, 7, S129-S129.	1.7	0
184	Updated guidelines for the diagnosis and management of high blood pressure: implications for clinical practice in nephrology. <i>Kidney International</i> , 2018, 93, 768-770.	5.2	3
185	Market Competition and Health Outcomes in Hemodialysis. <i>Health Services Research</i> , 2018, 53, 3680-3703.	2.0	16
186	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2018, 71, 851-865.	1.9	362
187	Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 555-563.	11.4	81
188	Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia. <i>American Journal of Hematology</i> , 2018, 93, E154-E156.	4.1	6
189	Benefits and risks of intensive blood pressure lowering in advanced chronic kidney disease. <i>Journal of Internal Medicine</i> , 2018, 284, 106-107.	6.0	5
190	Antihypertensive medication withholding practices in hemodialysis: A survey study of patients and providers. <i>Hemodialysis International</i> , 2018, 22, 415-418.	0.9	3
191	Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. <i>American Journal of Nephrology</i> , 2018, 47, 40-47.	3.1	123
192	Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. <i>American Journal of Hematology</i> , 2018, 93, 683-690.	4.1	100
193	Associations of lipoproteins with cardiovascular and infection-related outcomes in patients receiving hemodialysis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 481-487.e14.	1.5	8
194	Perioperative THR-184 and AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 670-679.	6.1	35
195	Chronic kidney disease care models in low- and middle-income countries: a systematic review. <i>BMJ Global Health</i> , 2018, 3, e000728.	4.7	57
196	Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. <i>Kidney International</i> , 2018, 93, 1475-1482.	5.2	41
197	Unplanned Emergency Department Visits and Hospital Admissions Following Ureteroscopy: Do Ureteral Stents Make a Difference?. <i>Urology</i> , 2018, 117, 44-49.	1.0	23
198	Incident CKD after Radical or Partial Nephrectomy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 207-216.	6.1	55

#	ARTICLE	IF	CITATIONS
199	Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 260-267.	6.1	106
200	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. <i>Circulation</i> , 2018, 137, 134-143.	1.6	134
201	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2018, 71, 352-361.	1.9	104
202	Causes of Death after a Hospitalization with AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1001-1010.	6.1	71
203	Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. <i>New England Journal of Medicine</i> , 2018, 378, 603-614.	27.0	399
204	FP152EFFECT OF BARDOXOLONE METHYL TREATMENT ON URINARY ALBUMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE - POST-HOC ANALYSIS FROM BEAM AND BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i27-i27.	0.7	2
205	The Terrible Toll of the Kidney Shortage. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2775-2776.	6.1	40
206	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1816-1824.	4.5	14
207	Would government compensation of living kidney donors exploit the poor? An empirical analysis. <i>PLoS ONE</i> , 2018, 13, e0205655.	2.5	11
208	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. <i>Journal of the American Heart Association</i> , 2018, 7, e009326.	3.7	79
209	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	2.5	14
210	Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1644-1645.	2.0	2
211	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1113-1117.	2.3	14
212	SP104DECREASES IN WEIGHT WITH BARDOXOLONE METHYL IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i379-i379.	0.7	2
213	Ferumoxylol for the treatment of iron deficiency anemia. <i>Expert Review of Hematology</i> , 2018, 11, 829-834.	2.2	35
214	Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System. <i>JAMA Internal Medicine</i> , 2018, 178, 1358.	5.1	24
215	Use of Estimating Equations for Dosing Antimicrobials in Patients with Acute Kidney Injury Not Receiving Renal Replacement Therapy. <i>Journal of Clinical Medicine</i> , 2018, 7, 211.	2.4	8
216	Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 693-707.	1.4	10

#	ARTICLE	IF	CITATIONS
217	Dialysis versus Medical Management at Different Ages and Levels of Kidney Function in Veterans with Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2169-2177.	6.1	34
218	Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 34, 1924-1931.	0.7	5
219	Acute Kidney Injury Due to Diarrheal Illness Requiring Hospitalization: Data from the National Inpatient Sample. <i>Journal of General Internal Medicine</i> , 2018, 33, 1520-1527.	2.6	12
220	A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxylol versus ferric carboxymaltose in iron deficiency anemia". <i>American Journal of Hematology</i> , 2018, 93, E232-E233.	4.1	0
221	Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. <i>American Journal of Hypertension</i> , 2018, 31, 97-107.	2.0	25
222	Comparing Simultaneous Liver-Kidney Transplant Strategies. <i>Transplantation</i> , 2018, 102, e219-e228.	1.0	9
223	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches"Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. <i>American Heart Journal</i> , 2018, 205, 42-52.	2.7	44
224	Bioelectrical Impedance Analysis Measures and Clinical Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 662-672.	1.9	37
225	Mandating Staffing Ratios in Hemodialysis Facilities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1110-1112.	4.5	13
226	FO022BARDOXOLONE METHYL PREVENTS EGFR DECLINE IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i10-i10.	0.7	2
227	Randomized trial of intravenous iron-induced hypophosphatemia. <i>JCI Insight</i> , 2018, 3, .	5.0	127
228	Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study. <i>PLoS Medicine</i> , 2018, 15, e1002532.	8.4	44
229	Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 156.	7.4	213
230	Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1933-1942.	6.1	78
231	Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1851-1858.	6.1	92
232	Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis. <i>Kidney International</i> , 2017, 91, 746-754.	5.2	78
233	Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial. <i>Kidney International</i> , 2017, 91, 1186-1192.	5.2	55
234	Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 146.	7.4	122

#	ARTICLE	IF	CITATIONS
235	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 737-746.	1.7	58
236	Utility in Treating Kidney Failure in End-Stage Liver Disease With Simultaneous Liver-Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1111-1119.	1.0	26
237	Home Dialysis in the Prospective Payment System Era. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2993-3004.	6.1	52
238	Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2132.	7.4	4
239	Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1128-1138.	4.5	21
240	Effects of Intensive BP Control in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2812-2823.	6.1	364
241	Factors Associated with Frailty and Its Trajectory among Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1100-1108.	4.5	120
242	Prehabilitation for kidney transplant candidates: Is it time?. <i>Clinical Transplantation</i> , 2017, 31, e13020.	1.6	39
243	Thyroid function in end stage renal disease and effects of frequent hemodialysis. <i>Hemodialysis International</i> , 2017, 21, 534-541.	0.9	13
244	Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. <i>Kidney International</i> , 2017, 92, 238-247.	5.2	158
245	HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes. <i>Scientific Reports</i> , 2017, 7, 43728.	3.3	28
246	Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. <i>Drugs in R and D</i> , 2017, 17, 159-166.	2.2	3
247	Hemodialysis Hospitalizations and Readmissions: The Effects of Payment Reform. <i>American Journal of Kidney Diseases</i> , 2017, 69, 237-246.	1.9	22
248	Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 315-322.	4.5	122
249	Can twice weekly hemodialysis expand patient access under resource constraints?. <i>Hemodialysis International</i> , 2017, 21, 445-452.	0.9	27
250	Infrequent Provision of Palliative Care to Patients with Dialysis-Requiring AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1744-1752.	4.5	9
251	Associations of Body Mass Index and Body Fat With Markers of Inflammation and Nutrition Among Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2017, 70, 817-825.	1.9	40
252	Effectiveness of Quality Improvement Strategies for the Management of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1601-1614.	4.5	19

#	ARTICLE	IF	CITATIONS
253	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.7	76
254	Receipt of Nephrology Care and Clinical Outcomes Among Veterans With Advanced CKD. American Journal of Kidney Diseases, 2017, 70, 705-714.	1.9	24
255	Donation, Not Disease! A Multiple-Hit Hypothesis on Development of Post-Donation Kidney Disease. Current Transplantation Reports, 2017, 4, 320-326.	2.0	11
256	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ Global Health, 2017, 2, e000453.	4.7	11
257	Declining Rates of Hip Fracture in End-Stage Renal Disease: Analysis From the 2003â€“2011 Nationwide Inpatient Sample. Journal of Bone and Mineral Research, 2017, 32, 2297-2303.	2.8	14
258	Re-evaluation of re-hospitalization and rehabilitation in renal research. Hemodialysis International, 2017, 21, 422-429.	0.9	5
259	Consolidation in the Dialysis Industry, Patient Choice, and Local Market Competition. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 536-545.	4.5	20
260	30-Day Readmissions After an Acute Kidney Injury Hospitalization. American Journal of Medicine, 2017, 130, 163-172.e4.	1.5	61
261	Hyperprolactinemia in endâ€“stage renal disease and effects of frequent hemodialysis. Hemodialysis International, 2017, 21, 190-196.	0.9	30
262	Sarcopenia among patients receiving hemodialysis: weighing the evidence. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 57-68.	7.3	80
263	Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?. Urology, 2017, 100, 65-71.	1.0	25
264	Estimating the Risk of Radiocontrast-Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 653-659.	6.1	182
265	Predialysis volume overload and patientâ€“reported sleep duration and quality in patients receiving hemodialysis. Hemodialysis International, 2017, 21, 133-141.	0.9	10
266	Prevalence of chronic kidney disease and risk factors for its progression: A cross-sectional comparison of Indians living in Indian versus U.S. cities. PLoS ONE, 2017, 12, e0173554.	2.5	21
267	Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS ONE, 2017, 12, e0188712.	2.5	22
268	Cost of Acute Kidney Injury in Hospitalized Patients. Journal of Hospital Medicine, 2017, 12, 70-76.	1.4	162
269	Abstract P145: Screening Rates for the Diagnostic Workup of Resistant Hypertension. Hypertension, 2017, 70, .	2.7	0
270	Declining Rates of Inpatient Parathyroidectomy for Primary Hyperparathyroidism in the US. PLoS ONE, 2016, 11, e0161192.	2.5	22

#	ARTICLE	IF	CITATIONS
271	Hip Fracture in Patients With Non-Dialysis-Requiring Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1803-1809.	2.8	123
272	Understanding barriers to home-based and self-care in-center hemodialysis. <i>Hemodialysis International</i> , 2016, 20, 235-241.	0.9	12
273	Results of human factors testing in a novel Hemodialysis system designed for ease of patient use. <i>Hemodialysis International</i> , 2016, 20, 643-649.	0.9	12
274	Antihypertensive medications and sexual function in women. <i>Journal of Hypertension</i> , 2016, 34, 1224-1231.	0.5	31
275	How to Diagnose Solutions to a Quality of Care Problem. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 901-907.	4.5	49
276	How to Begin a Quality Improvement Project. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 893-900.	4.5	104
277	How to Sustain Change and Support Continuous Quality Improvement. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 916-924.	4.5	110
278	How to Measure and Interpret Quality Improvement Data. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 908-914.	4.5	33
279	ISCHEMIA in chronic kidney disease: improving the representation of patients with chronic kidney disease in cardiovascular trials. <i>Kidney International</i> , 2016, 89, 1178-1179.	5.2	4
280	Early to Dialyze. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2171.	7.4	12
281	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2673.	7.4	991
282	Association of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality among Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 626-632.	4.5	80
283	The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 984-991.	0.7	16
284	The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. <i>Contemporary Clinical Trials</i> , 2016, 48, 119-124.	1.8	21
285	Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?. <i>Kidney International</i> , 2016, 90, 460-462.	5.2	5
286	Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. <i>American Journal of Nephrology</i> , 2016, 44, 130-140.	3.1	13
287	Metabolic Profiling of Impaired Cognitive Function in Patients Receiving Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3780-3787.	6.1	47
288	SO0300 ONE YEAR EFFICACY AND SAFETY OF INTRAVENOUS (IV) ETELCALCETIDE (AMG 416) IN PATIENTS ON HEMODIALYSIS (HD) WITH SECONDARY HYPERPARATHYROIDISM (SHPT). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i13-i14.	0.7	3

#	ARTICLE	IF	CITATIONS
289	Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?. <i>European Urology</i> , 2016, 70, 227-230.	1.9	24
290	Analyzing Health-Related Quality of Life in the EVOLVE Trial. <i>Medical Decision Making</i> , 2016, 36, 965-972.	2.4	19
291	Risk prediction to inform surveillance of chronic kidney disease in the US Healthcare Safety Net: a cohort study. <i>BMC Nephrology</i> , 2016, 17, 57.	1.8	7
292	Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1260-1267.	4.5	80
293	Cinacalcet, dialysate calcium concentration, and cardiovascular events in the <scp>EVOLVE</scp> trial. <i>Hemodialysis International</i> , 2016, 20, 421-431.	0.9	19
294	Characterizing Frailty Status in the Systolic Blood Pressure Intervention Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 649-655.	3.6	131
295	How to Use Quality Improvement Tools in Clinical Practice: A Primer for Nephrologists. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 891-892.	4.5	6
296	Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. <i>Hypertension</i> , 2016, 67, 550-555.	2.7	17
297	The Effect of Increased Frequency of Hemodialysis on Volume-Related Outcomes: A Secondary Analysis of the Frequent Hemodialysis Network Trials. <i>Blood Purification</i> , 2016, 41, 277-286.	1.8	37
298	Misclassification of Obesity by Body Mass Index Among Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2016, 67, 709-711.	1.9	9
299	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3129-3138.	6.1	50
300	Validating Appetite Assessment Tools Among Patients Receiving Hemodialysis. , 2016, 26, 103-110.		25
301	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 539-546.	4.5	20
302	Managing Hypertension in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 40-43.	6.1	21
303	Long-Term Effects of Frequent In-Center Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1830-1836.	6.1	91
304	The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. <i>Journal of Human Hypertension</i> , 2016, 30, 204-209.	2.2	13
305	Sex differences in obesity, dietary habits, and physical activity among urban middle-class Bangladeshis. <i>International Journal of Health Sciences</i> , 2016, 10, 363-72.	0.4	9
306	Effects of physician payment reform on provision of home dialysis. <i>American Journal of Managed Care</i> , 2016, 22, e215-23.	1.1	17

#	ARTICLE	IF	CITATIONS
307	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , 2015, 18, 1079-1087.	0.3	16
308	Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis. <i>American Journal of Nephrology</i> , 2015, 42, 134-140.	3.1	84
309	Improving Care after Acute Kidney Injury: A Prospective Time Series Study. <i>Nephron</i> , 2015, 131, 43-50.	1.8	35
310	Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 654-662.	1.9	5
311	Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial. <i>Pharmaceutical Statistics</i> , 2015, 14, 242-251.	1.3	17
312	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2015, 162, 258-265.	3.9	128
313	Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 106-113.	1.9	19
314	A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5. <i>American Journal of Kidney Diseases</i> , 2015, 65, 728-736.	1.9	117
315	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.	4.5	75
316	Dialysis Plus Do Not Resuscitate—Not a Contradiction. <i>JAMA Internal Medicine</i> , 2015, 175, 1035.	5.1	1
317	Risk Factors for Infection-Related Hospitalization in In-Center Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2170-2180.	4.5	39
318	Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease. <i>Nephron</i> , 2015, 129, 29-33.	1.8	51
319	Navigating Toward Research Success in Times of Uncertainty: Funding Opportunities for Early Career Investigators in Nephrology. <i>American Journal of Kidney Diseases</i> , 2015, 65, 381-383.	1.9	6
320	Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease. <i>Kidney International</i> , 2015, 88, 178-185.	5.2	53
321	Provider Visits and Early Vascular Access Placement in Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1990-1997.	6.1	17
322	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.	1.6	259
323	Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis. , 2015, 25, 351-356.		141
324	Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. <i>American Journal of Kidney Diseases</i> , 2015, 66, 459-468.	1.9	93

#	ARTICLE	IF	CITATIONS
325	Outcomes of Infection-Related Hospitalization in Medicare Beneficiaries Receiving In-Center Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2015, 65, 754-762.	1.9	40
326	Provider Visit Frequency and Vascular Access Interventions in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 269-277.	4.5	12
327	Association of bioimpedance spectroscopy-based volume estimation with postdialysis hypotension in patients receiving hemodialysis. <i>Hemodialysis International</i> , 2015, 19, 536-542.	0.9	12
328	Rehospitalizations and Emergency Department Visits after Hospital Discharge in Patients Receiving Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3141-3150.	6.1	69
329	Ambulatory Care after Acute Kidney Injury: An Opportunity to Improve Patient Outcomes. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 71.	1.1	67
330	Risk prediction models for contrast induced nephropathy: systematic review. <i>BMJ, The</i> , 2015, 351, h4395.	6.0	137
331	Cardiovascular and Renal Outcomes Trials—Is There a Difference?. <i>American Journal of Cardiology</i> , 2015, 116, 982-988.	1.6	3
332	The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 800-807.	4.5	107
333	Evaluating Risk of ESRD in the Urban Poor. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1434-1442.	6.1	13
334	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1466-1475.	6.1	163
335	Planning for Hemodialysis. , 2015, , 751-764.		0
336	Physician Visits and 30-Day Hospital Readmissions in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2079-2087.	6.1	82
337	Bardoxolone Methyl in Type 2 Diabetes and Advanced Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1767-1769.	27.0	27
338	Prognostic Stratification in Older Adults Commencing Dialysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 1033-1039.	3.6	20
339	Comparison of Hospitalization Rates among For-Profit and Nonprofit Dialysis Facilities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 73-81.	4.5	31
340	Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) Daily Trial. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 168-178.	0.7	45
341	Characteristics and Performance of Minority-Serving Dialysis Facilities. <i>Health Services Research</i> , 2014, 49, 971-991.	2.0	20
342	Anticoagulation, delivered dose and outcomes in <sc>CRRT</sc>: The program to improve care in acute renal disease (<sc>PICARD</sc>). <i>Hemodialysis International</i> , 2014, 18, 641-649.	0.9	16

#	ARTICLE	IF	CITATIONS
343	Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. <i>International Journal of Cancer</i> , 2014, 134, 2245-2252.	5.1	114
344	Effects of Frequent Hemodialysis on Perceived Caregiver Burden in the Frequent Hemodialysis Network Trials. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 936-942.	4.5	50
345	Association between Body Composition and Frailty among Prevalent Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 381-389.	6.1	134
346	Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis. <i>Forum for Health Economics and Policy</i> , 2014, 17, 53-77.	0.8	12
347	Thienopyridine Use After Coronary Stenting in Low Income Patients Enrolled in Medicare Part D Receiving Maintenance Dialysis. <i>Journal of the American Heart Association</i> , 2014, 3, e001356.	3.7	10
348	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001363.	3.7	105
349	Estimation of 24-Hour Urine Phosphate Excretion From Spot Urine Collection: Development of a Predictive Equation. , 2014, 24, 194-199.		15
350	Reply. <i>Urology</i> , 2014, 83, 779-780.	1.0	0
351	Lowering Blood Pressure to Lower the Risk of Cardiovascular Events in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 900-902.	1.9	1
352	Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma. <i>Urology</i> , 2014, 83, 774-780.	1.0	85
353	A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1053-1060.	0.7	64
354	Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. <i>Journal of Human Hypertension</i> , 2014, 28, 18-24.	2.2	59
355	Temporal Trends in the Incidence, Treatment and Outcomes of Hip Fracture After First Kidney Transplantation in the United States. <i>American Journal of Transplantation</i> , 2014, 14, 943-951.	4.7	70
356	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	1.7	139
357	Urine Electrolyte Composition and Diuretic Therapy in Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 697-698.	3.9	4
358	Long-Term Safety and Efficacy of a Novel Iron-Containing Phosphate Binder, JTT-751, in Patients Receiving Hemodialysis. , 2014, 24, 261-267.		51
359	Calibration of the Brief Food Frequency Questionnaire Among Patients on Dialysis. , 2014, 24, 151-156.e1.		11
360	Comparison of Self-reportâ™Based and Physical Performanceâ™Based Frailty Definitions Among Patients Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2014, 64, 600-607.	1.9	75

#	ARTICLE	IF	CITATIONS
361	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2014, 160, 143.	3.9	0
362	Reforming Medicare's Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism. <i>Health Services Research</i> , 2014, 49, n/a-n/a.	2.0	0
363	Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 430-437.	0.7	10
364	Characteristics and Performance of Minority-Serving Dialysis Facilities. , 2014, 49, 971.		2
365	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	3.1	82
366	Trends in Acute Kidney Injury, Associated Use of Dialysis, and Mortality After Cardiac Surgery, 1999 to 2008. <i>Annals of Thoracic Surgery</i> , 2013, 95, 20-28.	1.3	82
367	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1250-1258.	2.8	47
368	Effects of 6-Times-Weekly Versus 3-Times-Weekly Hemodialysis on Depressive Symptoms and Self-reported Mental Health: Frequent Hemodialysis Network (FHN) Trials. <i>American Journal of Kidney Diseases</i> , 2013, 61, 748-758.	1.9	52
369	Longitudinal Measures of Serum Albumin and Prealbumin Concentrations in Incident Dialysis Patients: The Comprehensive Dialysis Study. , 2013, 23, 91-97.		32
370	66 DIABETIC SEVERITY AND RISK OF KIDNEY STONE DISEASE. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
371	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2492-2503.	27.0	844
372	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4834-4844.	3.6	63
373	Sensitization from transfusion in patients awaiting primary kidney transplant. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2908-2918.	0.7	69
374	Cinacalcet for Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2013, 368, 1842-1845.	27.0	16
375	Association of Physical Activity with Survival among Ambulatory Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 248-253.	4.5	117
376	Piecewise Analysis of Patient Survival after Onset of AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1679-1684.	4.5	15
377	Temporal Trends in the Incidence, Treatment, and Outcomes of Hip Fracture in Older Patients Initiating Dialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1336-1342.	4.5	67
378	Effects of Frequent Hemodialysis on Ventricular Volumes and Left Ventricular Remodeling. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2106-2116.	4.5	70

#	ARTICLE	IF	CITATIONS
379	Variation in Nephrologist Visits to Patients on Hemodialysis across Dialysis Facilities and Geographic Locations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 987-994.	4.5	33
380	Oh! What a Tangled Web We Weave. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1066-1067.	4.5	2
381	Systematic evaluation of environmental and behavioural factors associated with all-cause mortality in the United States National Health and Nutrition Examination Survey. <i>International Journal of Epidemiology</i> , 2013, 42, 1795-1810.	1.9	109
382	Prevention of Contrast-Induced AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1618-1631.	4.5	94
383	Effect of frequent hemodialysis on residual kidney function. <i>Kidney International</i> , 2013, 83, 949-958.	5.2	186
384	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2841-2850.	0.7	21
385	High prevalence of type 2 diabetes among the urban middle class in Bangladesh. <i>BMC Public Health</i> , 2013, 13, 1032.	2.9	39
386	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2013, 159, 382.	3.9	56
387	Venous Thromboembolism. <i>Circulation</i> , 2012, 126, 1937-1938.	1.6	1
388	Determinants of Left Ventricular Mass in Patients on Hemodialysis. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 251-261.	2.6	87
389	Ongoing Clinical Trials in AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 861-873.	4.5	76
390	Effects of Six versus Three Times per Week Hemodialysis on Physical Performance, Health, and Functioning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 782-794.	4.5	95
391	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.	0.7	45
392	The effect of frequent hemodialysis on nutrition and body composition: Frequent Hemodialysis Network Trial. <i>Kidney International</i> , 2012, 82, 90-99.	5.2	65
393	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	27.0	805
394	Frailty, Dialysis Initiation, and Mortality in End-Stage Renal Disease. <i>Archives of Internal Medicine</i> , 2012, 172, 1071-7.	3.8	267
395	Homelessness and CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1094-1102.	4.5	28
396	Validation of Reported Predialysis Nephrology Care of Older Patients Initiating Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1078-1085.	6.1	39

#	ARTICLE	IF	CITATIONS
397	Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. Journal of the American Society of Nephrology: JASN, 2012, 23, 1663-1673.	6.1	88
398	Toward the Optimal dose Metric in Continuous Renal Replacement Therapy. International Journal of Artificial Organs, 2012, 35, 413-424.	1.4	22
399	Effects of Phosphate Binders in Moderate CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1407-1415.	6.1	486
400	Acute Kidney Injury and Mortality in Hospitalized Patients. American Journal of Nephrology, 2012, 35, 349-355.	3.1	399
401	Effects of Frequent Hemodialysis on Measures of CKD Mineral and Bone Disorder. Journal of the American Society of Nephrology: JASN, 2012, 23, 727-738.	6.1	137
402	Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodialysis International, 2012, 16, 188-197.	0.9	22
403	Challenges to enrollment and randomization of the frequent hemodialysis network (FHN) daily trial. Journal of Nephrology, 2012, 25, 302-309.	2.0	22
404	The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney International, 2011, 80, 1080-1091.	5.2	450
405	Association of Self-reported Physical Activity With Laboratory Markers of Nutrition and Inflammation: The Comprehensive Dialysis Study. , 2011, 21, 429-437.		39
406	Chronic Kidney Disease and Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2011, 58, 1162-1164.	2.8	5
407	Assessment and management of vascular disease risk in patients with chronic kidney disease. Journal of Clinical Lipidology, 2011, 5, 251-260.	1.5	0
408	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology Dialysis Transplantation, 2011, 26, 1327-1339.	0.7	491
409	The Phosphate Binder Equivalent Dose. Seminars in Dialysis, 2011, 24, 41-49.	1.3	114
410	Baseline Physical Performance, Health, and Functioning of Participants in the Frequent Hemodialysis Network (FHN) Trial. American Journal of Kidney Diseases, 2011, 57, 101-112.	1.9	63
411	Baseline Characteristics of Participants in the Frequent Hemodialysis Network (FHN) Daily and Nocturnal Trials. American Journal of Kidney Diseases, 2011, 57, 90-100.	1.9	36
412	The 2011 ESRD Prospective Payment System: An Uncontrolled Experiment. American Journal of Kidney Diseases, 2011, 57, 542-546.	1.9	15
413	Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Intensive Care Medicine, 2011, 37, 241-248.	8.2	239
414	Modeled Urea Distribution Volume and Mortality in the HEMO Study. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1129-1138.	4.5	15

#	ARTICLE	IF	CITATIONS
415	Racial Ethnic Differences in Rates and Determinants of Deceased Donor Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 743-751.	6.1	103
416	Model to Predict Mortality in Critically Ill Adults with Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2114-2120.	4.5	88
417	Predialysis Nephrology Care of Older Patients Approaching End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2011, 171, 1371.	3.8	62
418	Risk of Cardiovascular Events after Infection-Related Hospitalizations in Older Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1708-1713.	4.5	45
419	Effluent Volume in Continuous Renal Replacement Therapy Overestimates the Delivered Dose of Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 467-475.	4.5	100
420	Burden on caregivers as perceived by hemodialysis patients in the Frequent Hemodialysis Network (FHN) trials. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2316-2322.	0.7	85
421	World Kidney Day 2011. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 397-398.	6.1	5
422	Aspirin and Arteriovenous Graft Thrombosis in Hemodialysis: Just What the Doctor Ordered?. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 595-597.	6.1	3
423	Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. <i>Journal of Human Hypertension</i> , 2011, 25, 98-105.	2.2	45
424	Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 441-442.	0.4	4
425	Infection-Related Hospitalizations in Older Patients With ESRD. <i>American Journal of Kidney Diseases</i> , 2010, 56, 522-530.	1.9	95
426	Off-Label Use of Phosphate Binders in Non-Dialysis-Dependent CKD. <i>American Journal of Kidney Diseases</i> , 2010, 56, 813-816.	1.9	1
427	On the relative safety of intravenous iron formulations: New answers, new questions. <i>American Journal of Hematology</i> , 2010, 85, 643-644.	4.1	14
428	<i>Insight</i> : Effects of Reduced Intradialytic Urea Generation Rate and Residual Renal Clearance on Modeled Urea Distribution Volume and Kt/V in Conventional, Daily, and Nocturnal Dialysis. <i>Seminars in Dialysis</i> , 2010, 23, 19-24.	1.3	7
429	Reexploring Differences among For-Profit and Nonprofit Dialysis Providers. <i>Health Services Research</i> , 2010, 45, 633-646.	2.0	44
430	GFR estimating equations, CKD prevalence and the public health. <i>Journal of Internal Medicine</i> , 2010, 267, 354-356.	6.0	1
431	Determinants of Cardiac Autonomic Dysfunction in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1821-1827.	4.5	61
432	Can Rescaling Dose of Dialysis to Body Surface Area in the HEMO Study Explain the Different Responses to Dose in Women versus Men?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1628-1636.	4.5	63

#	ARTICLE	IF	CITATIONS
433	Low level of self-reported physical activity in ambulatory patients new to dialysis. <i>Kidney International</i> , 2010, 78, 1164-1170.	5.2	146
434	Hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary?. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 366-371.	2.9	6
435	Weekend Hospital Admission, Acute Kidney Injury, and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 845-851.	6.1	97
436	Kidney Disease, Hospitalized Hypertension, and Cardiovascular Events: Cause or Consequence?. <i>Circulation</i> , 2010, 121, 2160-2161.	1.6	3
437	Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 102-107.	0.7	97
438	Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1916-1923.	0.7	38
439	Chronic Kidney Disease in the Urban Poor. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 828-835.	4.5	63
440	In-Center Hemodialysis Six Times per Week versus Three Times per Week. <i>New England Journal of Medicine</i> , 2010, 363, 2287-2300.	27.0	898
441	Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. <i>Kidney International</i> , 2010, 77, 637-644.	5.2	81
442	Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. <i>Kidney International</i> , 2010, 77, 630-636.	5.2	68
443	Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. <i>Critical Care</i> , 2010, 14, R82.	5.8	342
444	Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2010, 362, 590-599.	27.0	1,023
445	Regional Variation in Kidney Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 152-159.	4.5	11
446	Phosphorus binders and survival: need for randomized trials. <i>Nature Reviews Nephrology</i> , 2009, 5, 368-370.	9.6	1
447	Functional Status of Elderly Adults before and after Initiation of Dialysis. <i>New England Journal of Medicine</i> , 2009, 361, 1539-1547.	27.0	849
448	Fetuin-A and Change in Body Composition in Older Persons. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4492-4498.	3.6	44
449	Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. <i>Kidney International</i> , 2009, 76, 893-899.	5.2	483
450	The Comprehensive Dialysis Study (CDS). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 645-650.	4.5	48

#	ARTICLE	IF	CITATIONS
451	Preexisting Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1914-1919.	4.5	91
452	Is there "Cherry Picking" in the ESRD Program? Perceptions from a Dialysis Provider Survey. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 772-777.	4.5	27
453	Characteristics of Uninsured Americans with Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2009, 24, 917-922.	2.6	45
454	The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: A systematic review. <i>Hemodialysis International</i> , 2009, 13, 347-359.	0.9	40
455	A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology. <i>Hemodialysis International</i> , 2009, 13, 360-362.	0.9	20
456	Increased fluid intake does not augment capacity to lay down new collagen in nursing home residents at risk for pressure ulcers: A randomized, controlled clinical trial. <i>Wound Repair and Regeneration</i> , 2009, 17, 780-788.	3.0	12
457	An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard. <i>Value in Health</i> , 2009, 12, 80-87.	0.3	166
458	Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. <i>Critical Care</i> , 2009, 13, 310.	5.8	53
459	Frailty and Chronic Kidney Disease: The Third National Health and Nutrition Evaluation Survey. <i>American Journal of Medicine</i> , 2009, 122, 664-671.e2.	1.5	279
460	Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. <i>Kidney International</i> , 2009, 76, 422-427.	5.2	888
461	Medication errors in chronic kidney disease: one piece in the patient safety puzzle. <i>Kidney International</i> , 2009, 76, 1123-1125.	5.2	28
462	<i>Dialysis Research</i>: Surface Area Normalized <i>Kt</i>/<i>V</i>: A Method of Rescaling Dialysis Dose to Body Surface Area—Implications for Different Size Patients by Gender. <i>Seminars in Dialysis</i> , 2008, 21, 415-421.	1.3	58
463	<i>Editorials</i>: Comparison of Proposed Alternative Methods for Rescaling Dialysis Dose: Resting Energy Expenditure, High Metabolic Rate Organ Mass, Liver Size, and Body Surface Area. <i>Seminars in Dialysis</i> , 2008, 21, 377-384.	1.3	45
464	Neighborhood Poverty and Kidney Transplantation Among US Asians and Pacific Islanders with End-stage Renal Disease. <i>American Journal of Transplantation</i> , 2008, 8, 2402-2409.	4.7	43
465	The risk of acute renal failure in patients with chronic kidney disease. <i>Kidney International</i> , 2008, 74, 101-107.	5.2	448
466	Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States. , 2008, 18, 323-331.		31
467	Kidney dysfunction and fatal cardiovascular disease—an association independent of atherosclerotic events: Results from the Health, Aging, and Body Composition (Health ABC) study. <i>American Heart Journal</i> , 2008, 155, 62-68.	2.7	89
468	Optimal Initiation and Management of Dialysis Therapy. <i>Operations Research</i> , 2008, 56, 1428-1449.	1.9	36

#	ARTICLE	IF	CITATIONS
469	Higher Serum Creatinine Concentrations in Black Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 992-997.	4.5	62
470	A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1332-1338.	4.5	61
471	Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2311-2318.	0.7	92
472	Diagnosis, Epidemiology and Outcomes of Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 844-861.	4.5	431
473	Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2008, 359, 7-20.	27.0	1,611
474	Lessons for Successful Study Enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 955-961.	4.5	27
475	Cost-Effectiveness of Frequent In-Center Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1792-1797.	6.1	40
476	Toward the Promise of Renal Replacement Therapy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 839-840.	6.1	10
477	Phosphorus balance and mineral metabolism with 3h daily hemodialysis. <i>Kidney International</i> , 2007, 71, 336-342.	5.2	72
478	Frequent Hemodialysis Network (FHN) randomized trials: Study design. <i>Kidney International</i> , 2007, 71, 349-359.	5.2	176
479	Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 2533-2539.	1.6	147
480	Significance of Frailty among Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2960-2967.	6.1	545
481	Race and Mortality after Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2740-2748.	6.1	41
482	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 898-905.	4.5	144
483	Octogenarians and Nonagenarians Starting Dialysis in the United States. <i>Annals of Internal Medicine</i> , 2007, 146, 177.	3.9	446
484	Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury*. <i>Critical Care Medicine</i> , 2007, 35, 2755-2761.	0.9	131
485	Community-based incidence of acute renal failure. <i>Kidney International</i> , 2007, 72, 208-212.	5.2	461
486	Chronic Kidney Disease Mineral Bone Disorder and Health-Related Quality of Life Among Incident End-Stage Renal-Disease Patients. , 2007, 17, 305-313.		20

#	ARTICLE	IF	CITATIONS
487	Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 173-179.	1.6	300
488	Kidney Function as a Predictor of Loss of Lean Mass in Older Adults: Health, Aging and Body Composition Study. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1578-1584.	2.6	30
489	A Simulation Model to Estimate the Cost and Effectiveness of Alternative Dialysis Initiation Strategies. <i>Medical Decision Making</i> , 2006, 26, 535-549.	2.4	19
490	Acute renal failure after endovascular vs open repair of abdominal aortic aneurysm. <i>Journal of Vascular Surgery</i> , 2006, 43, 460-466.e2.	1.1	151
491	Cystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study. <i>Journal of Cardiac Failure</i> , 2006, 12, 601-607.	1.7	68
492	Association of body size with health status in patients beginning dialysis. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 543-549.	4.7	46
493	Chronic Kidney Disease and Functional Limitation in Older People: Health, Aging and Body Composition Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 750-756.	2.6	177
494	The tortoise and hare on hemodialysis: Does slow and steady win the race?. <i>Kidney International</i> , 2006, 70, 24-25.	5.2	8
495	Mortality after acute renal failure: Models for prognostic stratification and risk adjustment. <i>Kidney International</i> , 2006, 70, 1120-1126.	5.2	245
496	Challenging the Validity of the EPO Index. <i>American Journal of Kidney Diseases</i> , 2006, 47, 166.e1-166.e13.	1.9	50
497	PTH and the Risks for Hip, Vertebral, and Pelvic Fractures Among Patients on Dialysis. <i>American Journal of Kidney Diseases</i> , 2006, 47, 149-156.	1.9	271
498	Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation. <i>Surgery</i> , 2006, 140, 990-999.	1.9	56
499	Fetuin-A and kidney function in persons with coronary artery disease—data from the heart and soul study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2144-2151.	0.7	67
500	Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2543-2548.	0.7	198
501	Cystatin C and Measures of Physical Function in Elderly Adults: The Health, Aging, and Body Composition (HABC) Study. <i>American Journal of Epidemiology</i> , 2006, 164, 1180-1189.	3.4	99
502	Survival by Dialysis Modality in Critically Ill Patients with Acute Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3132-3138.	6.1	95
503	Timing of Initiation of Dialysis in Critically Ill Patients with Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 915-919.	4.5	299
504	The Case against Calcium-Based Phosphate Binders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 697-703.	4.5	89

#	ARTICLE	IF	CITATIONS
505	Cystatin C and Mortality Risk in the Elderly. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 254-261.	6.1	195
506	Evolving Practices in Critical Care and Potential Implications for Management of Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 869-873.	4.5	23
507	Studying the Prevention of Acute Kidney Injury: Lessons from an 18th-Century Mathematician: Table 1.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1124-1127.	4.5	27
508	Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium A^- Phosphate. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 305-312.	4.5	64
509	Update on adverse drug events associated with parenteral iron. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 378-382.	0.7	405
510	Tesio Catheter Access for Long-term Maintenance Hemodialysis. <i>Radiology</i> , 2006, 241, 284-290.	7.3	15
511	Risks for End-Stage Renal Disease, Cardiovascular Events, and Death in Hispanic versus Non-Hispanic White Adults with Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2892-2899.	6.1	140
512	Declining Mortality in Patients with Acute Renal Failure, 1988 to 2002. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1143-1150.	6.1	499
513	Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1688-1694.	6.1	415
514	Decrease in Thoracic Vertebral Bone Attenuation With Calcium-Based Phosphate Binders in Hemodialysis. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 764-772.	2.8	132
515	Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. <i>Kidney International</i> , 2005, 68, 1793-1800.	5.2	499
516	Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. <i>Kidney International</i> , 2005, 68, 2794-2800.	5.2	66
517	Health-related quality of life and estimates of utility in chronic kidney disease. <i>Kidney International</i> , 2005, 68, 2801-2808.	5.2	235
518	Achieving NKF-K/DOQI \AA , \AA bone metabolism and disease treatment goals with cinacalcet HCl. <i>Kidney International</i> , 2005, 67, 760-771.	5.2	290
519	Chronic kidney disease and cognitive impairment in menopausal women. <i>American Journal of Kidney Diseases</i> , 2005, 45, 66-76.	1.9	152
520	Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 290-295.	6.7	104
521	Insulin resistance in critically ill patients with acute renal failure. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, F259-F264.	2.7	108
522	Medicare ESRD Prospective Payment System: Weighing the Evidence. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1164-1165.	6.1	13

#	ARTICLE	IF	CITATIONS
523	Differential Mortality and Transplantation Rates among Asians and Pacific Islanders with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3711-3720.	6.1	45
524	Beyond Framingham: Cardiovascular Risk Profiling in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1539-1541.	6.1	26
525	Suicide in the United States End-Stage Renal Disease Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 774-781.	6.1	144
526	Calcification or Classification?. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 293-295.	6.1	14
527	Control of Hypertension in Adults With Chronic Kidney Disease in the United States. <i>Hypertension</i> , 2005, 45, 1119-1124.	2.7	151
528	Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2134-2140.	6.1	614
529	Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. <i>American Journal of Nephrology</i> , 2005, 25, 393-399.	3.1	17
530	Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2765-2774.	0.7	115
531	Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3365-3370.	6.1	2,887
532	Dialysis session length (Kt/V) as a determinant of the adequacy of dialysis. <i>Seminars in Nephrology</i> , 2005, 25, 90-95.	1.6	17
533	Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. <i>American Heart Journal</i> , 2005, 149, 820-825.	2.7	225
534	Serum Blood Urea Nitrogen as an Independent Marker of Subsequent Mortality Among Patients With Acute Coronary Syndromes and Normal to Mildly Reduced Glomerular Filtration Rates. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1781-1786.	2.8	117
535	Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2208-2218.	6.1	2,350
536	Renalism. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2462-2468.	6.1	281
537	Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. <i>Circulation</i> , 2004, 110, 3667-3673.	1.6	185
538	A 43-Year-Old Woman With Chronic Renal Insufficiency. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1252.	7.4	3
539	Determinants of progressive vascular calcification in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1489-1496.	0.7	258
540	Coronary and aortic calcifications in patients new to dialysis. <i>Hemodialysis International</i> , 2004, 8, 265-272.	0.9	35

#	ARTICLE	IF	CITATIONS
541	Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. <i>Kidney International</i> , 2004, 66, 1266-1271.	5.2	99
542	Spectrum of acute renal failure in the intensive care unit: The PICARD experience. <i>Kidney International</i> , 2004, 66, 1613-1621.	5.2	763
543	Cognitive Impairment in Chronic Kidney Disease. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1863-1869.	2.6	380
544	Physical and sexual function in women with chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 868-876.	1.9	37
545	Screening to prevent coronary events or screening to detect obstruction?. <i>American Journal of Kidney Diseases</i> , 2004, 43, 940.	1.9	3
546	On the relative safety of parenteral iron formulations. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1571-1575.	0.7	136
547	Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. <i>New England Journal of Medicine</i> , 2004, 351, 1296-1305.	27.0	9,843
548	Association of body size with outcomes among patients beginning dialysis. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 324-332.	4.7	248
549	Analgesia in patients with ESRD: a review of available evidence. <i>American Journal of Kidney Diseases</i> , 2003, 42, 217-228.	1.9	136
550	Reasons for non-enrollment in a cohort study of ARF: the Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. <i>American Journal of Kidney Diseases</i> , 2003, 42, 507-512.	1.9	28
551	The Decline in Residual Renal Function in Hemodialysis Is Slow and Age Dependent. <i>Hemodialysis International</i> , 2003, 7, 17-22.	0.9	13
552	Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 232-240.	2.1	9
553	Acute Renal Failure Definitions and Classification. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2178-2187.	6.1	463
554	Slowing the Progression of Vascular Calcification in Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S310-S314.	6.1	45
555	The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S148-S153.	6.1	545
556	The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2003, 23, 307-314.	3.1	98
557	In critically ill patients with acute renal failure, outcomes, not dollars, should drive modality choice *. <i>Critical Care Medicine</i> , 2003, 31, 644-646.	0.9	17
558	Diuretics, Mortality, and Nonrecovery of Renal Function in Acute Renal Failure. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2547.	7.4	604

#	ARTICLE	IF	CITATIONS
559	The Severity of Secondary Hyperparathyroidism in Chronic Renal Insufficiency is GFR-Dependent, Race-Dependent, and Associated with Cardiovascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2762-2769.	6.1	157
560	Refining Predictive Models in Critically Ill Patients with Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1350-1357.	6.1	328
561	Cardiac calcification in adult hemodialysis patients. <i>Journal of the American College of Cardiology</i> , 2002, 39, 695-701.	2.8	1,020
562	Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. , 2002, 12, 170-176.		19
563	Renal insufficiency with monoclonal gammopathy and urticarial vasculitis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 203-207.	1.9	6
564	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. <i>Kidney International</i> , 2002, 62, 245-252.	5.2	1,316
565	Suspected iron dextran-related adverse drug events in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2001, 37, 743-749.	1.9	126
566	Gridlock on the Road to Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2001, 37, 435-437.	1.9	7
567	Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. <i>Kidney International</i> , 2001, 60, 333-340.	5.2	182
568	Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease. <i>Kidney International</i> , 2001, 59, 1121-1127.	5.2	214
569	“Wishing Don’t Make it So” Why We Need a Randomized Clinical Trial of High-Intensity Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2850-2853.	6.1	20
570	Hyperparathyroidism and dialysis vintage. <i>Clinical Nephrology</i> , 2000, 54, 295-300.	0.7	27
571	Metabolic and Monetary Costs of Avoidable Parenteral Nutrition Use. <i>Journal of Parenteral and Enteral Nutrition</i> , 1999, 23, 109-113.	2.6	94
572	Issues in Evaluating the Cost-Effectiveness of Dialysis. <i>Seminars in Dialysis</i> , 1999, 12, 355-358.	1.3	3
573	A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. <i>Clinical Nephrology</i> , 1999, 51, 18-26.	0.7	110
574	Dialysis: Cost-effective SUPPORT for patients with acute renal failure. <i>American Journal of Kidney Diseases</i> , 1998, 31, 545-549.	1.9	6
575	Current and Future Therapies for the Medical Management of Secondary Hyperparathyroidism. <i>Seminars in Dialysis</i> , 1998, 11, 267-270.	1.3	5
576	Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 692-698.	6.1	190

#	ARTICLE	IF	CITATIONS
577	Assessing the Nutritional Status of Patients with End-Stage Renal Disease. <i>Seminars in Dialysis</i> , 1997, 10, 108-114.	1.3	12
578	Intensity of Dialysis in Established Acute Renal Failure. <i>Seminars in Dialysis</i> , 1996, 9, 476-480.	1.3	7
579	Performance characteristics of a dialysis-related amyloidosis questionnaire.. <i>Journal of the American Society of Nephrology: JASN</i> , 1996, 7, 1235-1240.	6.1	8
580	Cost-effectiveness of cancer screening in end-stage renal disease. <i>Archives of Internal Medicine</i> , 1996, 156, 1345-50.	3.8	13
581	Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients.. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 6, 75-81.	6.1	236
582	Non-immunologic predictors of chronic renal allograft failure: data from the United Network of Organ Sharing. <i>Kidney International, Supplement</i> , 1995, 52, S48-51.	0.1	4
583	Association of Apolipoprotein L-1 polymorphisms with blood pressure in three multi-ethnic African studies. <i>Journal of Global Health Reports</i> , 0, , .	1.0	0